

ANDRÉ ROGATKO

CURRICULUM VITAE

March 24, 2016

Personal History: Business Address: 8700 Beverly Blvd., PACT Suite 900C
Los Angeles, CA 90048, phone: 310-423-3316
Born: São Paulo, Brazil
U.S. Citizen
Married

Education: 1973-1976 B.S., Biological Science, São Paulo University,
São Paulo, Brazil
1977-1978 M.S., Genetics/Statistics, São Paulo University,
São Paulo, Brazil, Summa cum laude
1979-1983 Ph.D., Genetics/Statistics, São Paulo
University, São Paulo, Brazil, Summa cum laude
Postdoctoral Fellow, Division of Genetic Epidemiology,
Department of Epidemiology and Biostatistics, Memorial
Sloan Kettering Cancer Center, 1985-1987

Licensure: Not Applicable

Board Certification: Not Applicable

Professional Experience: Director, Biostatistics and Bioinformatics Research Center,
Samuel Oschin Comprehensive Cancer Institute, Cedars-
Sinai Medical Center, 2011-
Adjunct Professor, Department of Medicine, David Geffen
School of Medicine, UCLA, 2011-
Director, Research Informatics Core, Samuel Oschin
Comprehensive Cancer Institute, Cedars-Sinai Medical
Center, 2009-
Associate Director for Biostatics Research and Informatics,
Samuel Oschin Comprehensive Cancer Institute, Cedars-
Sinai Medical Center, 2008-
Director, Biostatistics and Bioinformatics Core, Samuel
Oschin Comprehensive Cancer Institute, Cedars-Sinai
Medical Center, 2008-
Research Scientist IV, Department of Medicine, Division of
Hematology and Oncology, Cedars-Sinai Medical Center,
2008-
Adjunct Professor, Department of Biostatistics and
Bioinformatics, The Rollins School of Public Health, Emory
University, 2008-2012

Professor, Department of Biostatistics and Bioinformatics,
The Rollins School of Public Health, Emory University;
2004-2008

Professor, Department of Hematology and Oncology,
School of Medicine, Emory University, 2004-2008

Associate Director for Biostatistics Research and Informatics,
Winship Cancer Institute, 2004-2008

Chairman, Department of Biostatistics, Fox Chase Cancer
Center, Philadelphia, PA, 1999-2004

Member (with Tenure), Division of Population Science, Fox
Chase Cancer Center, Philadelphia, PA, 1995-2004.

Associate Member, Division of Population Science, Fox
Chase Cancer Center, Philadelphia, PA, 1992-1995

Staff Scientist (Statistician), Biostatistics Research and
Informatics Unit, International Agency for Research on
Cancer - World Health Organization, Lyon, 1990-1992

Assistant Biostatistician, Division of Biostatistics,
Department of Epidemiology and Biostatistics Memorial
Sloan-Kettering Cancer Center, New York, NY, 1978-1990

Research Fellow, Division of Genetic Epidemiology,
Department of Epidemiology and Biostatistics, Memorial
Sloan-Kettering Cancer Center, New York, NY, 1985- 1987

Course Director, Cornell University - Graduate School of
Medical Sciences, New York, NY, 1988-1989

Assistant Professor, Department of Statistics, Institute of
Mathematics and Statistics, São Paulo University, São
Paulo, Brazil, 1983-1985

Associate Professor, Mackenzie University, São Paulo,
Brazil, 1979-1980

Assistant Professor, Mackenzie University, São Paulo,
Brazil, 1977-1979

Professional Activities:

Committee Memberships

National and International

Aids and Related Research Study Section, NIH, Ad Hoc
Reviewer, 1995

Special Review Committee, RFA Molecular Epidemiology of
Prostate Carcinogenesis, NCI, 1995

Special Review Committee, RFA Cancer Therapy with
Biological Response Modifiers, NCI, 1996

Clinical Oncology Study Section, NIH, 2000-2001

Subcommittee E – Cancer Epidemiology, Prevention & Control, NCI, 2000- 2001

Special Emphasis Panel – National Heart, Lung and Blood Institute, NIH, 2000-2004

NCI Special Emphasis Panel – SPORE in Myeloma and Genitourinary Cancer, 2004

Subcommittee D – Clinical Studies, National Cancer Institute Initial Review Group, NCI, 2002-2008

Subcommittee C – Basic & Preclinical, National Cancer Institute Initial Review Group, NCI, 2005

Data Monitoring Safety Board, Airway Biology and Disease Program, NIH, 2003-2014

NCI Gene Therapy Cluster Review, 2005

Avon-NCI Progress for Patients Awards, 2005

Reviewer of the Intramural Research Program, Biostatistics Branch, Division of Cancer Epidemiology and Genetics, NCI, Bethesda, MD, 4/24-26, 2006

Subcommittee E – Cancer Epidemiology, Prevention & Control, NCI, 2006

NIH Biostatistical Methods and Research Design Study Section, 2007

ASCO Scientific Program Committee 2008-2010

Clinical Oncology Study Section, NIH, 2009

Recombinant DNA Advisory Committee, NIH, 2010

NCI Special Emphasis Panel – Molecular Mechanism and Targeted Therapies, 2011

NCI Special Emphasis Panel – SPORE in Breast, Endometrial and Skin Cancers, 2012

NCI Special Emphasis Panel - NCI Program Project Review Panel Meeting II, 2012

NCI Special Emphasis Panel - NCI Program Project Review Panel Meeting IV, 2012

NCI Special Emphasis Panel - Chemo Prevention Study Section, 2012

neuroNEXT Council ZNS1 SRB G(63), 2013

NCI Special Emphasis Panel - NCI Program Project Review Panel Meeting III, 2013

Leadership Group for an HIV Vaccines Clinical Network, 2013

NCI Special Emphasis Panel – Provocative Questions: Cancer Therapy & Outcomes, 2013

NCI Special Emphasis Panel - NCI Program Project Review Panel Meeting IV, 2013

NCI Special Emphasis Panel - NCI SPORE Panel II, 2014

Statistical and Data Coordinating Center for Clinical Research in Infectious Diseases, 2014

NCI Omnibus R21/R03 Special Emphasis Panel, 2014

NCI Special Emphasis Panel - NCI SPORE Panel III, 2014

NCI Omnibus R21/R03 Special Emphasis Panel, 2014

NCI Special Emphasis Panel - NCI Program Project Review Panel Meeting II, 2015

Institutional

Research Review Committee, Fox Chase Cancer Center, 1992-2004

Clinical Translational Review Committee, Winship Cancer Institute, 2004-2008

Protocol Review Committee, Children's Healthcare of Atlanta Aflac Cancer Center & Blood Disorders Service, 2004-2008

Editorial

Referee: American Journal of Human Genetics, Biometrics, Genetic Epidemiology, International Journal of Cancer, Journal of Clinical Oncology, Journal of Statistical Planning and Inference, Journal of the National Cancer Institute, Proceedings of the National Academy of Sciences – USA, Statistics in Medicine, The American Statistician, Women and Cancer, Statistical Science, Journal of the American Statistical Association, Contemporary Clinical Trials, Bioinformatics, Entropy, Statistics and Probability Letters.

Scientific Societies (* - current member)

1978 Brazilian Society of Genetics

1986 American Society of Human Genetics

1987* American Statistical Association

1989 Institute of Mathematical Statistics

1989* Biometric Society

1991 International Genetic Epidemiology Society

2007 International Society for Clinical Biostatistics

2008 American Society of Clinical Oncology

2009 American Association for Cancer Research

CSMC Professional Activities: Protocol Review and Monitoring Committee 2008-2014, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, since 2009. Information Sciences Committee, since 2010. CS Personalized Medicine Initiative, 2011. CTSI Operations Committee, since 2011, Clinical Scholars Steering & Oversight Committee, since 2009, SOCCI Senior Leadership Committee, since 2013, SOCCI Cancer Center Support Grant Executive Committee, SOCCI, since 2013, SOCCI Developmental Funds Committee, since 2012.

Research Grants and Fellowships Received:

Active Support

Co-Investigator, California Breast Cancer Center Research Program, 21OB-0136, "STOP Heart Disease in Breast Cancer Survivors," PI: Goodman, Period 09/01/15 – 08/31/18, Effort: 5%.

Co-Investigator, NIH/NCI, R01 CA188480-01A1, "Design of Cancer Phase I/II Clinical Trials Using Drug Combinations of Cytotoxic and Biologic Agents," PI: Tighiouart, [Current Period] Direct Costs: \$207,500, Period 09/17/2014 – 08/31/2019, Effort: 10%.

Co-Investigator, Erika Glazer Family Foundation, "Women's Ischemic Syndrome Evaluation (WISE) Coronary Vascular Dysfunction - Continuation," PI: Bairey-Merz, Total Awarded: \$7.2M, Period 09/01/2014 – 08/31/2019, Effort 5%.

Co-Investigator, NIH/NHLBI, R01 HL089765, "High Performance Automated System for Analysis of Fast Cardiac SPECT," PI: Slomka, [Current Period] Direct Costs: \$384,667, Period 08/06/2014 – 05/31/2018, Effort 2%.

Co-Investigator, NIH/NIDDK, 1R21 DK103198-01, "Treatment of Pituitary Cushing Disease with a Selective CDK Inhibitor, R-roscovitine," PI: Melmed, [Current Period] Direct Costs: \$150,000, Period 06/01/2014 – 05/31/2016, Effort: 5%.

Principal Investigator, FDA/Seattle Children's Hospital, 5R01 FS004099-03 "Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD," PI: Kean, [Current Period] Direct Costs \$17,816 (CSMC Subaward), Period 05/01/2014 – 04/30/2016, Effort 2%.

Co-Investigator, NIH/NCI, 2R01 CA108646-07A1 "TGF- β Signals in Prostate Stromal-Epithelial Interactions", PI: Bhowmick, [Current Period] Direct Costs \$164,442, Period 09/12/2012 – 06/30/2017, Effort 3%.

Co-Investigator, Program Leader, NIH/NCATS, 1UL TR000124-01 “UCLA Clinical and Translational Science Institute”, PI: Dubinett, Direct Costs \$2,017,329 (CSMC Subcontract), Period 06/01/2011 – 02/29/2016, Effort 15%.

Previous Support

1. Core Director, NIH/NCI, P01 CA098912-10 “Prostate Cancer Bone Metastasis: Biology and Targeting,” PI: Chung, [Current Period] Direct Costs \$123,376, Period 08/03/2013 – 02/28/2015, Effort 8%.
2. Co-Investigator, NHLBI, 3R01 HL090957-04S1 “Women’s Ischemia Syndrome Evaluation (WISE) Coronary Vascular Dysfunction,” PI: Bairey-Merz, Direct Costs \$299,401, Period 09/18/2013 – 08/31/2014, Effort 3%.
3. Co-Investigator, Co-Director for Biostatistics, NIH, P01 DK046763 “IBD: Genetic and Immunopathologic Mechanisms,” PI: Targan, Direct Costs: \$179,368, Period 09/01/2010 – 08/31/2015, Effort 5%.
4. Principal Investigator, Robert W. Woodruff Health Sciences Center Fund, “Evaluation of Patient Characteristics as Predictors of Acute Treatment Toxicity,” Direct Cost \$100,000, 09/01/2006 – 08/31/2007.
5. Principal Investigator, Georgia Cancer Coalition, Distinguished Cancer Clinicians and Scientists Program, Direct Cost \$750,000, 08/01/2005 – 07/31/2010.
6. Co-Investigator, NIH/NCI, “Targeting Cell Signaling in Lung Cancer to Enhance Therapeutic Efficacy,” Direct Cost \$7.9M, 05/01/2006-05/31/2011.
7. Co-Investigator, NIH/NCI, “Role of ATBF-1 Inactivation in the Development and Progression of Prostate Cancer,” Direct Cost \$1.3M, 04/14/2006-02/28/2011.
8. Co-Investigator, NIH/NCI, “Chemoprevention of Head and Neck Cancer with ZD1839 and Celecoxib for Former Smokers,” Direct Cost \$473,119, 09/15/2004-07/31/2009.
9. Co-Investigator, NIH/NCI, “Planning Grant for NCI Cancer Research Center ‘Comprehensive Cancer Center,’” P20 CA103735, Direct Cost \$1.9M, 09/01/2003 – 08/30/2008.
10. Co-Investigator, NIH/NCI, “SPORE in Head and Neck Cancer,” Direct Cost \$12.5M , 8/23/07-6/30/12.
11. Co-Investigator, Salix Pharmaceuticals, Inc., “Rifaximin for Preventing Acute Graft Versus Host Disease,” Direct Cost \$60K, 10/3/07 – 9/30/08.
12. Principal Investigator, NIH, “Etiology of Toxic Response to Cancer Treatment,” R03 CA92769, Direct Costs \$100,000, 2002-2005.

13. Principal Investigator, Translational Research Institutional Grant, "Patient Characteristics as Predictors of Toxicity of Cancer Treatment," Direct Costs \$301,869, 2003-2005.
14. Principal Investigator, NIH Institutional Grant, "Dosing Paradigm in Early Cancer Clinical Trials: Database for Developing New Statistical Approaches," P30 CA06927, 1998.
15. Principal Investigator, The Development of Breast Cancer Research at Fox Chase Cancer Center, 1994-1995.
16. Principal Investigator, NIH General Medical Sciences, "Statistical inference in multipoint linkage," R01 GM4579-01 A 1, Direct Costs \$295,304, 1993-1996.
17. Principal Investigator, The Pew Charitable Trusts, Young Investigator Award, Direct Costs \$200,000, 1993-1994.
18. Principal Investigator, American Cancer Society, "Bayesian approach for meta-analysis of controlled clinical trials: general model with covariates," Institutional Grant 114-L, 1989-1990.
19. Co-Investigator, NIH NCI "NMR Studies of Human Cancer," P.I.: Brown T, 1992-2000.
20. Co-Investigator, ACS PBR-86 "Nurse Initiated Communication Skills for Breast Patients," P.I.: A. Barsevick, 1993-1996.
21. Co-Investigator, NIH CA61204 "Bio-Behavioral Lung Cancer Prevention Program," P.I.: Lerman C, 1993-1997.
22. Co-Investigator, NIH NCI-CM57208-79 "Phase I Clinical Trials of Anticancer Agents," P.I.: O'Dwyer P, 1995-1998.
23. Co-Investigator, NIH HGOI 189 "Coping with Genetic Risk for Breast and Ovarian Cancer," P.I.: Daly M, 1994-1997.
24. Co-Investigator, DAMD 17-94-J-4425 "Establishment at the Fox Chase Network Breast Cancer Risk Registry," P.I.: Daly M, 1994-1997.
25. Co-Investigator, NIH 1R01CA81867 "Communicating Genetic Test Results to the Family," P.I.: Daly M, 1999-2003.
26. Co-Investigator, DOD DAMD 1718650 "Ovarian Cancer Prevention Program," P.I.: Engstrom P, 1998-2001.
27. Co-Investigator, NIH 1R01 CA75795 "Colon Cancer Screening for Cancer Patients' Families," P.I.: Manne S, 1998-2002.
28. Co-Investigator, NIH 1R21CA762541 "Optimized Cancer Chemotherapy via Pharmacodynamic Models," P.I.: Gallo J, 1999-2001.
29. Co-Investigator, NIH N01-CN-95037 "Evaluation of In Vivo and In Vitro Pharmacology and Toxicology of Preventive Agents Using Human Mutant Cells from Dominantly Heritable Cancer," P.I.: Knudson A, 1999-2003.

30. Co-Investigator, NIH 1P01 CA83638 "SPORE in Ovarian Cancer," P.I.: Ozols R, 1999-2004.
31. Co-Investigator, DAMD17-00-1-0568 "Quality of Life after Prophylactic Oophorectomy," P.I.: Daly M, 2000-2003.
32. Co-Investigator, DAMD 17-00-1-0248 "Pharmacogenetic Factors Contributing to Variation in Response to Tamoxifen and Raloxifene," P.I.: Raftogianis R, 2000-2003.
33. Co-Investigator, NIH R01 GM61756 "Pharmacogenetics of Sulfate Conjugation," P.I.: Raftogianis R, 2002-2006.
34. Co-Investigator, NIH P30 CA06927 "Comprehensive Cancer Center Program," P.I.: Young R, 2000-2005.
35. Co-Investigator, NIH R21 CA92992 "Evaluation of the Vaccine rF-CEA," P.I.: von Mehren M, 2001-2003.
36. Predoctoral Fellow, Computing Center of São Paulo University, São Paulo, Brazil, 1977-1980.
37. Predoctoral Fellow, Brazilian National Council of Research (CNPq), 1978-1983.
38. Researcher, Brazilian National Council of Research (CNPq), 1983-1985.
39. Postdoctoral Fellow, Division of Genetic Epidemiology, Department of Epidemiology and Biostatistics, MSKCC, 1985-1987.

Research Interests: Design of cancer clinical trials, genetic epidemiology, risk prediction

Invited Lectures and Presentations (past 3 years):

1. Dose Finding with Overdose Control in Cancer Clinical Trials, 11th Brazilian Bayesian Statistics Meeting, Amparo, São Paulo, Brazil, 2012.
2. Integrated Web 1 Portal For Escalation With Overdose Control (EWOC), Fourth Annual Cancer Institute Research Poster Presentation, Cedars-Sinai Medical Center, Los Angeles, CA, 2012.
3. Incorporating Patient's Characteristics in Cancer Phase I Clinical Trials Using Time to DLT: Escalation with Overdose Control (EWOC), Fourth Annual Cancer Institute Research Poster Presentation, Cedars-Sinai Medical Center, Los Angeles, CA, 2012.
4. Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials, Fourth Annual Cancer Institute Research Poster Presentation, Cedars-Sinai Medical Center, Los Angeles, CA, 2012.
5. Dose-Finding with Drug Combinations in Cancer Phase I Clinical Trials Using Conditional Escalation with Overdose Control (EWOC), Western North American Region of the International Biometrics Society Meetings, Los Angeles, CA, 2013.

6. FDA and Innovative Designs: Case Study of a Missed Opportunity, Western North American Region of the International Biometrics Society Meetings, Los Angeles, CA, 2013.
7. Web-EWOC: Interactive Web Tool for Describing and Conducting Dose Finding in Cancer Phase I Clinical Trials, Western North American Region of the International Biometrics Society Meetings, Los Angeles, CA, 2013.
8. Decisions, Decisions, Decisions, Department of Statistics, University of São Paulo, São Paulo, Brazil, 2013.
9. Designing a Dose Finding Trial Using EWOC, Department of Statistics, Federal University of São Carlos, São Paulo, Brazil, 2013.
10. Designing a Dose Finding Trial Using EWOC, Department of Statistics, University of São Paulo, São Paulo, Brazil, 2013.
11. FDA and Innovative Designs: Case Study of a Missed Opportunity, Joint Statistical Meetings, Montreal, Quebec, Canada, 2013.
12. FDA and Innovative Designs: Case Study of a Missed Opportunity, 12th Brazilian Bayesian Statistics Meeting, Atibaia, São Paulo, Brazil, 2014.
13. Maximizing the Number of Patients Receiving Optimal Doses in Cancer Dose Finding Trials with Escalation With Overdose Control (EWOC), Western North American Region of the International Biometrics Society Meetings, Mānoa, Hawaii, 2014.
14. Maximizing the Number of Patients Receiving Optimal Doses in Cancer Dose Finding Trials with Escalation With Overdose Control. 4th Early Phase Adaptive Trials Workshop, Charleston, SC, 2014.
15. Misuse of Statistical Methods and Reproducibility Problems in Science. Department of Statistics. Universidade Federal de São Carlos, Brazil, 2015.
16. Mini-course *Dose Finding with Escalation with Overdose Control in Cancer Clinical Trials*, 4th Workshop on Probabilistic and Statistical Methods (WPSM) at the Universidade Federal de São Carlos, Brazil, February 1-3, 2016

CSMC Teaching Activities and/or Other Off-Campus Teaching:

1. Design of Phase I Trials, Hematology/Oncology Grand Rounds, Cedars-Sinai Medical Center, 2011.
2. Introduction to Bayesian Statistics, Graduate and Clinical Scholars Program, Cedars-Sinai Medical Center, Los Angeles, 2011.
3. Designs to Establish Safety - Escalation with Overdose Control, Clinical & Translational Research Workshop, Cedars-Sinai Medical Center, Los Angeles, 2011.
4. Introduction to Biostatistics, Lecture for Radiology Residents, Cedars-Sinai Medical Center, Los Angeles, 2012.
5. Why Statistics?, Statistics in Medical Research Lecture Series - Fall 2012, Cedars-Sinai Medical Center, 2012.
6. Decisions, Decision, Decisions, Statistics in Medical Research Lecture Series - Fall 2012, Cedars-Sinai Medical Center, 2012.
7. Designs to Establish Safety – Escalation With Overdose Control. Clinical & Translational Research Workshop, Cedars-Sinai Medical Center, Los Angeles, 2013.

8. Why Statistics?, Statistics in Medical Research Lecture Series - Fall 2013, Cedars-Sinai Medical Center, 2013.
9. Decisions, Decision, Decisions, Statistics in Medical Research Lecture Series - Fall 2013, Cedars-Sinai Medical Center, 2013.
10. Maximizing the Number of Patients Receiving Optimal Doses in Phase I Trials, Hematology/Oncology Grand Rounds, Cedars-Sinai Medical Center, 2014.
11. Designs to Establish Safety – Escalation With Overdose Control. Clinical & Translational Research Workshop, Cedars-Sinai Medical Center, Los Angeles, 2014
12. Why Statistics?, Statistics in Medical Research Lecture Series - Fall 2014, Cedars-Sinai Medical Center, 2014.
13. Decisions, Decision, Decisions, Statistics in Medical Research Lecture Series - Fall 2014, Cedars-Sinai Medical Center, 2014.
14. Designs to Establish Safety – Escalation With Overdose Control. Clinical & Translational Research Workshop, Cedars-Sinai Medical Center, Los Angeles, 2015

Research Papers (peer-reviewed):

A. Research Papers – Peer-Reviewed

1. Moreira-Filho CA, Andrews NW, **Rogatko A**, Frota-Pessoa O. 1978. Testosterone sensitivity of lymphocytes from a patient with testicular feminization syndrome and controls. Braz. J. Genet. 1(2): 145-153.
2. Richieri-Costa A, **Rogatko A**, Levisky R, Finkel N, Frota-Pessoa O. 1981. Autosomal dominant late adult spinal muscular atrophy, type Finkel. Am. J. Med. Genet. 9: 119-128.
3. Otto PA, Frota-Pessoa O, Fragoso SC, Junqueira PC, Munoz D, L'Abbate M, **Rogatko A**. 1982. Probabilities of true paternity for individuals not excluded through tests with genetic markers. Braz. J. Genet. 5(2): 383-382.
4. Zatz M, Karp LE, **Rogatko A**. 1982. Pyruvate-kinase (PK) and creatine-phosphokinase (CPK) in normal pregnancy and its implication in genetic counseling of Duchenne muscular dystrophy (DMD). Am. J. Med. Genet. 13: 257-262.
5. Perondini ALP, Otto PA, Templeton AR, **Rogatko A**. 1983. Evidence for assortative mating systems related to the polytene chromosome bands polymorphism in *Sciara ocellaris* (Diptera, Sciaridae). J. Hered. 74: 283-288.
6. **Rogatko A**. 1983. Diallelic model combining selection and incomplete penetrance. J. Theor. Biol. 102: 1-6.
7. Levisky RB, Thomas C, Roisenberg I, Ferrari N, **Rogatko A**, Otto PA, Ferreira-Filho AA, Coelho E, Carelli CA, Frota-Pessoa O. 1983. Evaluation of the techniques for detection of hemophilia A heterozygotes. Braz. J. Genet. 4: 327-335.
8. Pereira CAB, **Rogatko A**. 1984. The Hardy-Weinberg equilibrium under a Bayesian perspective. Braz. J. Genet. 7: 689-707.

9. Rodrigues J, Bolfarine H, **Rogatko A**. 1985. A general theory of prediction in finite populations. Inter. Stat. Rev. 53: 239-254.
10. **Rogatko A**, Pereira CAB, Frota-Pessoa O. 1986. A Bayesian method for the estimation of penetrance: application to mandibulofacial and fronto-nasal dysostoses. Am. J. Med. Genet. 24: 231-246.
11. **Rogatko A**. 1986. The recurrence risks for isolated cases with incompletely penetrant X-linked conditions. Genet. Epidem. 3: 353-364.
12. **Rogatko A**, Auerbach AD. 1988. Segregation analysis with uncertain ascertainment: application to Fanconi anemia. Am. J. Hum. Genet. 42: 889-897.
13. **Rogatko A**. 1988. Evaluating the uncertainty of risk prediction in genetic counseling: a Bayesian approach. Am J. Med. Genet. 31: 513-519.
14. Sherman SL, **Rogatko A**, Turner G. 1988. Recurrence risks for relatives in families with an isolated case of fragile X syndrome. Am. J. Med. Genet. 31: 753-766.
15. Auerbach AD, **Rogatko A**, Schroeder-Kurth TM. 1989. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxibutane sensitivity. Blood 73: 391-396.
16. Scheinfeld J, Schaffer AJ, Cordon-Cardo C, **Rogatko A**, Fair W. 1989. Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N. Eng. J. Med. 320: 773-777.
17. Petrek JA, Peters MM, Nori S, Knauer C, Kinne DW, **Rogatko A**. 1990. Axillary lymphadenectomy: a prospective, randomized trial of 13 factors influencing drainage, including early or delayed arm mobilization. Ann. Surg. 125: 378-382.
18. Bevilacqua RG, Coit DG, **Rogatko A**, Younes RN, Brennan ME. 1990. Axillary dissection in melanoma: prognostic variables in node positive patients. Ann. Surg. 212: 125-13.
19. Vitelli CE, Cooper K, **Rogatko A**, Brennan MF. 1991. Cardiopulmonary resuscitation in cancer patients. J. Clin. Oncol. 9: 111-115.
20. Petrek JA, Dukoff R, **Rogatko A**. 1991. The prognosis of pregnancy-associated breast cancer. Cancer 67: 869-872.
21. Younes RN, **Rogatko A**, Vydellingum NA, Brennan MF. 1991. Effect of hypovolemia and transfusion on tumor growth in MCA-tumor bearing rats. Surgery 109: 307-312.
22. Bevilacqua RG, **Rogatko A**, Hajdu SI, Brennan MF. 1991. Prognostic factors in primary retroperitoneal soft tissue sarcomas. Arch. Surg. 126: 328-334.

23. Cersosimo E, Pisters PWT, Pesola G, **Rogatko A**, Vydelingum NA, Bajorunas D, Brennan MF. 1991. The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery 109: 459-467.
24. Brady MS, **Rogatko A**, Dent L, Shiu MH. 1991. Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Arch. Surg. 126: 359-364.
25. Younes RN, **Rogatko A**, Brennan MF. 1991. The influence of intraoperative hypotension and perioperative blood transfusion on prognosis of patients with complete resection of colorectal liver metastases. Ann. Surg. 214: 107-113.
26. Younes RN, **Rogatko A**, Brennan MF. 1991. The hemodynamic response to hemorrhage in tumor-bearing animals. Surgery 110: 508-513.
27. Coit D, **Rogatko A**, Brennan MF. 1991. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: a multivariate analysis. Ann. Surg. 214: 627-636.
28. Herr HR, Klein EA, **Rogatko A**. 1991. Local BCG failures in superficial bladder cancer: a multivariate analysis of risk factors influencing survival. Eur. Urol. 19: 97-100.
29. Rooij PD, **Rogatko A**, Brennan MF. 1991. Evaluation of palliative surgical procedures in unresectable pancreatic cancer. Br. J. Surg. 78: 1053-1058.
30. Pisters PWT, Cersosimo E, **Rogatko A**, Brennan MF. 1992. Insulin action on glucose and branched chain amino acid metabolism in cancer cachexia: differential effects of insulin. Surgery 111: 301-310.
31. Klein EA, Rogatko A, Herr HW. Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol. 1992 Mar;147(3):601-5. PubMed PMID: 1538437
32. Shah N, Valle OD, Edmondson R, Acampora G, Bedford RF, Dwyer D, Matarazzo D, **Rogatko A**. 1992. Esmolol infusion during nitroprusside-induced hypotension: impact on hemodynamics, ventricular performance and venous admixture. Cardiothorax Vase. Anesth. 6: 196-200.
33. **Rogatko A**. 1992. Bayesian approach for meta-analysis of controlled clinical trials. Commun. Statist-Theory Meth. 21: 1441-1462.
34. Zaïd K, **Rogatko A**. 1993. Note on a general algorithm for constructing Bayesian credible regions. J. Statist. Computa. Simul. 44:251-255.
35. **Rogatko A**, Zacks S. 1993. Ordering genes: controlling the decision error probabilities. Am. J. Hum. Genet. 52: 947-957.
36. Pignatelli B, Malaveille C, **Rogatko A**, Hautefeuille A, Thuillier P, Munoz N, Moulinier B, Berger F, DeMontclos H, Lambert R,

- Correa P, Ruiz B, Sobala GM, Schorah CJ, Axon ATR, Bartsch H. 1993. Mutagens N-nitroso compounds and their precursors in gastric juice from patients with and without precancerous lesions of the stomach. Eur. J. Cancer 29A:2031-2039.
37. Gwin JL, Klein-Szanto JP, Zhang S-Y, Agarwal P, **Rogatko A**, Keller SM. 1994. Loss of blood group antigen A is not a poor prognostic factor in non-small cell lung cancer. Ann. Surg. Oncol. 1:423-427.
38. Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, **Rogatko A**, Nash S, McAller C, Hamilton TC, Roby D, Young RC, Ozols RF, O'Dwyer PJ. 1994. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Cancer Research 54:709-717.
39. Hageboutros A, **Rogatko A**, Newman EM, McCleer C, Brennan J, LaCreta FP, Ozols RF, O'Dwyer PJ. 1994. Phase I study of phosphonacetyl-L-aspartate (PALA), 5-fluorouracil, and leucovorin in patients with advanced cancer. Cancer Chemother. Pharmacol.35: 205-212.
40. **Rogatko A**. 1995. Risk prediction with linked markers: Theory. Am. J. Med. Genetics 59:13-24.
41. **Rogatko A**, Rebbeck T, Zacks S. 1995. Risk prediction with linked markers: Pedigree Analysis. Am. J. Med. Genetics 59:23-32.
42. Pereira CAB, **Rogatko A**. 1996. Bayes estimate of the equilibrium parameter in a Markov chain: a medical application. Rev. Mat. Estat., São Paulo, 14:103-112.
43. Obasaju CK, Johnson SW, **Rogatko A**, Kilpatrick D, Brennan JM, Hamilton TC, Ozols RF, O'Dwyer PJ, Gallo JM. 1996. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin. Cancer Res. 2: 549-552.
44. Rebbeck TR, Jordan HA., Schnur RE, **Rogatko A**. 1997. Utility of linked markers in genetic counseling: estimation of carrier risks in X-linked ocular albinism. Am. J. Med. Genet. 70:58-66.
45. Montgomery RC, Hoffman JP, Riley LB, **Rogatko A**, Ridge JA, Eisenberg BL. 1997. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4:551-556 .
46. Viana M, **Rogatko A**, Rebbeck T. 1998. Statistical assessment of multi-valued diagnostic tests. Can. J. Stat. 26:657-668.
47. Babb J, **Rogatko A**, Zacks S. 1998. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 17:1103-1120
48. Rebbeck T, **Rogatko A**, Viana M. 1998. Evaluation of genotype data in clinical risk assessment: methods and application to BRCA1, BRCA2, and N-acetyl transferase-2 genotypes in breast cancer. Genet. Testing 1:157-164.

49. Zacks S, **Rogatko A**, Babb J. 1998. Optimal Bayesian-feasible dose escalation for cancer phase I trials. Stat. and Prob. Ltrs. 38:215-220.
50. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, **Rogatko A**, Leighton JC, Goldstein L. 1998. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clinical Cancer Research 4:1533-1542.
51. **Rogatko A**, Babb J, Jordan H, Zacks S. 1999. Constructing meiotic maps with known error probability. Genetic Epidemiol. 16:274-289.
52. Daly M, Farmer J, Harrop-Stein C, Montgomery S, Itzen M, Costalas JW, **Rogatko A**, Miller S, Balshem A, Gillespie D. 1999. Exploring family relationships in cancer risk counseling using the genogram. Cancer Epidemiol. Biomarkers Prev. 8:393-398.
53. Zekri A-RN, Bahnassi A.A, Bove B, Huang Y, Russo IH, **Rogatko A**, Shaarawy S, Shawki OA, Hamza M-R, Omer S, Khaled HM, Russo J. 1999. Allelic instability as a predictor of survival in Egyptian breast cancer patients. Intnatl. J. Oncol. 15:757-767.
54. Schilder RJ, Goldberg M, Millenson MM, Movsas B, **Rogatko A**, Rogers B, Langer CJ. 2000. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung. Lung Cancer 27:37-45.
55. von Mehren M, Arlen P, Ysang KY, **Rogatko A**, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. 2000. Pilot Study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6:2219-2228.
56. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, **Rogatko A**, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. 2001. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 58(1):59-64.
57. Babb JS, **Rogatko A**. 2001. Patient specific dosing in a cancer phase I clinical trial. Stat. Med. 20:2079-2090.
58. Chao C, Al-Saleem T, Brooks JJ, **Rogatko A**, Kraybill WG, Eisenberg B. 2001. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann. Surg. Oncol. 8:260-267.
59. Schilder RJ, Gallo JM, Millenson MM, Bookman MA, Weiner LM, **Rogatko A**, Rogers B, Padavic-Shallers K, Boente M, Rosenblum N, Adams AL, Ciccotto S, Ozols RE. 2001. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan

- with peripheral-blood stem-cell support as front-line therapy. J. Clin. Oncol. 19:1183-1194.
60. von Mehren M, Arlen P, Gulley J, **Rogatko A**, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM. 2001. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7(5):1181-1191.
 61. Cheng JD, Dunbrack RL Jr, Valianou M, **Rogatko A**, Alpaugh RK, Weiner LM. 2002. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 62(16):4767-4772.
 62. **Rogatko A**, Slifker MJ, Babb JS. 2002. Hardy-Weinberg equilibrium diagnostics. Theor. Popul. Biol. 62:251-257.
 63. Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, **Rogatko A**, Hudes GR. 2003. Weekly Bryostatins-1 in Metastatic Renal Cell Carcinoma: A Fox Chase Network Phase II Study. Clin. Cancer Research 9:109-114.
 64. Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK., Beard M, Lewis NL, McLaughlin S, **Rogatko A**, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. 2003. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 21(7):1301-1306.
 65. Brown T, Sigurdson E, Rogatko A, Broccoli D. Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann Surg Oncol. 2003 Oct;10(8):910-5. PubMed PMID: 14527910.
 66. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai D E, Schuster SJ, Stadtmayer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, **Rogatko A**, Mardirosian G, Goldenberg DM. 2003. Radioimmunotherapy of Non-Hodgkin's Lymphoma with ⁹⁰Y-DOTA Humanized Anti-CD22 IgG (⁹⁰Y-epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response? Journal of Nuclear Medicine 44(12)2000-2018.
 67. Lewis NL, Mullaney M, Mangan KF, Klumpp T, **Rogatko A**, Broccoli D. 2004. Lymphoid reconstitution: Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant. 33:71-78.
 68. Cheng J, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, **Rogatko A**. 2004. Individualized patient dosing in phase I clinical

- trials: the role of EWOC in PNU-214936. J. Clin. Oncol. 22(4):602-9.
69. Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, **Rogatko A**, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ. 2004. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol. 53(6):513-8.
70. **Rogatko A**, Babb JS, Wang H, Slifker MJ, Hudes G. 2004. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin. Cancer Res. 10(14):4645-51.
71. Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, **Rogatko A**, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR. 2004. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma. Haematologica 89(12):1484-91.
72. Borghaei H, Millenson M, Schilder R, Alden M, **Rogatko A**, Wang H, Padavic-Shaller K, Smith MR. 2004. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. Cancer 101(9):2034-41.
73. von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, **Rogatko A**. 2004. Phase II trial of Dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. 8(4):107-11.
74. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, **Rogatko A**, Wang H, Blanchard RL. 2005. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical Cancer Research 11(3):1226-36.
75. **Rogatko A**, Babb JS, Tighiouart M, Khuri FR, Hudes G. 2005. New paradigm in dose-finding trials: patient-specific dosing and beyond "phase I". Clinical Cancer Research, 11(15): 5342-6.
76. Tighiouart M, **Rogatko A**, Babb JS. 2005. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Statistics in Medicine, 24, 2183-2196.
77. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KMW, Papadimitrakopoulou V, Tighiouart M, **Rogatko A**, Khuri FR. 2005. Phase II Study of the Farnesyltransferase Inhibitor (FTI) Lonafarnib with Paclitaxel in Patients with Taxane-Refractory/Resistant Non-Small Cell Lung Cancer. Cancer, 104:561-9.
78. Sundermeyer ML, Meropol NJ, **Rogatko A**, Wang H, Cohen SJ. 2005. Changing Patterns of Bone and Brain Metastases in

- Patients with Colorectal Cancer. Clinical Colorectal Cancer, July; 5(2): 108-13.
79. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LWMM, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrin A, **Rogatko A**, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ. 2006. Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, July, 6(2):125-32.
80. Xu Z, Tighiouart M, **Rogatko A**. 2007. EWOC 2.0: Interactive Software for Dose Escalation in Cancer Phase I Clinical Trials. Drug Information Journal, 41(2):221-228.
81. Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis, N, Watkins-Bruner D, **Rogatko A**, Konski A. 2007. Phase I Trial of Preoperative Hypofractionated Intensity Modulated Radiation Therapy (IMRT) with Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer, International Journal of Radiation Oncology, Biology, Physics, 67(5):1389-1393.
82. **Rogatko A**, Schoeneck D, Jonas W, Tighiouart M, Khuri F, Porter A. 2007. Translation of Innovative Designs into Cancer Phase I Trials. Journal of Clinical Oncology, 25(31), 4982-4986.
83. Yezhelyev MV, Al-Hajj A, Morris C, Marcus A, Liu T, Lewis M, Cohen C, Zrazhevskiy P, Simons JW, **Rogatko A**, Nie S, Gao X, O'Regan RM. 2007. In Situ Molecular Profiling of Breast Cancer Biomarkers with Multicolor Quantum Dots. Advanced Materials, 19, 3146-3151.
84. Parker KP, Bliwise DL, Ribeiro M, Jain S, Vena CI, Kohles-Baker MK, **Rogatko A**, Xu Z, Harris WB. 2008. Sleep/Wake Patterns in Individuals with Advanced Cancer via Continuous Ambulatory Polysomnography. Journal of Clinical Oncology, 26(15):2464-72.
85. Cohen S, Alpaugh K, Palazzo I, Meropol N, **Rogatko A**, Xu Z, Hoffman J, Weiner L, Cheng, J. Fibroblast activation protein and its relationship to clinical outcome in resected pancreatic adenocarcinoma. Pancreas, 2008, 37 (2): 154-158.
86. **Rogatko A**, Ghosh P, Vidakovic B, Tighiouart M. Patient-Specific Dose Adjustment in the Cancer Clinical Trial Setting. Pharmaceutical Medicine. 2008;22(6):345-50
87. Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, **Rogatko A**, Osunkoya AO, Zayzafoon M, Chung L, Petros JA. Mitochondrial DNA Mutation Stimulates Prostate Cancer Growth in Bone Stromal Environment. Prostate. 2009;69(1):1-11.
88. Hanania NA, Sockrider M, Giraldo L, Valdez R, Flores E, Reibman J, et al. Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma. New England Journal of Medicine. 2009;360(15):1487-99.

89. H. Borghaei, K. Alpaugh, G. Hedlund, G. Forsberg, C. Langer, **A. Rogatko**, R. Hawkins, S. Dueland, U. Lassen and R. B. Cohen. 2009. Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 27(25): 4116-4123.
90. DiMango E, Holbrook JT, Simpson E, Reibman J, Richter J, Narula S, Prusakowski N, Mastronarde JG, Wise RA; American Lung Association Asthma Clinical Research Centers. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. Am J Respir Crit Care Med. 2009 Nov 1;180(9):809-16. PMID: 19661245
91. Kichun Sky Lee, M. Forrest Abouelinasr, Charlene W. Bayer, Sheryl G.A. Gabram, Boris Mizaikoff, **Rogatko A** and Brani Vidakovic. 2010. Mining Exhaled Volatile Organic Compounds for Breast Cancer Detection. Advances and Applications in Statistical Sciences 1(2): 327-342.
92. Qayed M, Thompson A, Applegate K, Haight A, **Rogatko A**, Chiang KY, Horan J. 2010. Is the updated Schwartz formula appropriate for assessing renal function prior to hematopoietic stem cell transplantation? Pediatr Blood Cancer. 2010 Jul 15;55(1):199-201. PMID: 20486187
93. Wang H, Bouzyk E, Kuehn A, Muller S, Chen Z, Khuri FR, Shin DM, **Rogatko A**, Tighiouart M. 2010. caGrid-Enabled caBIGTM Silver Level Compatible Head and Neck Cancer Tissue Database System. The Open Medical Informatics Journal, 2010, 4, 171-178.
94. Tighiouart M, **Rogatko A**. 2010. Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials. Statistical Science 25(2)217-226.
95. Astsaturon IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, **Rogatko A**, Xu Z, Watson JC, Weiner LM, Cohen SJ. 2010. Phase II and Coagulation Study of Bevacizumab with or without Docetaxel in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2010 May 7. [Epub ahead of print] PMID: 20458210
96. Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hes O, Svec A, Kida M, Vankalakunti M, Berel D, **Rogatko A**, Gown AM, Amin MB. 2011. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol. Feb;35(2):161-76. PMID: 21263237
97. Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook JT, Wise RA, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastronarde JG, Sockrider MM, Teague WG. 2012 Lansoprazole for children with

- poorly controlled asthma: a randomized controlled trial. JAMA. Jan 25;307(4):373-81. PMID: 22274684
98. Tighiouart M, Cook-Wiens G, **Rogatko A**. 2012. Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control, Journal of Probability and Statistics, vol. 2012, Article ID 567819, 10 pages, doi:10.1155/2012/567819
99. Tighiouart M, **Rogatko A**. 2012. Number of Patients per Cohort and Sample Size Considerations using Dose Escalation with Overdose Control. Journal of Probability and Statistics, vol. 2012 , Article ID 692725, 16 pages, doi:10.1155/2012/692725
100. Tighiouart M, Cook-Wiens G, **Rogatko A**. 2012. Escalation with Overdose Control using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials. Journal of Probability and Statistics, vol. 2012, Article ID 317634, 18 pages, 2012. doi:10.1155/2012/317634.
101. Harvey R D, Owonikoko T K, Lewis C M, Akintayo A, Chen Z, Tighiouart M, Ramalingam S S, Fanucchi M P, Nadella P, **Rogatko A**, Shin D M, El-Rayes B, Khuri F R, Kauh J S. 2013. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. British Journal of Cancer 108: 762-765. doi:10.1038/bjc.2012.604.
102. Qayed M, Langston A, Chiang KY, August K, Hilinski JA, Cole CR, **Rogatko A**, Bostick RM, Horan JT. 2013. Rifaximin for Preventing Acute Graft-Versus-Host Disease: Impact on Plasma Markers of Inflammation and T-cell Activation. Journal of Pediatric Hematology Oncology 35: E149-E152. doi: 10.1097/MPH.0b013e31827e56af.
103. Lang JE, Dozor AJ, Holbrook JT, Mougey E, Krishnan S, Sweeten S, Wise RA, Teague WG, Wei CY, Shade D, Lima JJ; American Lung Association-Asthma Clinical Research Centers. Biologic mechanisms of environmental tobacco smoke in children with poorly controlled asthma: results from a multicenter clinical trial. J Allergy Clin Immunol Pract. 2013 Mar;1(2):172-80. doi: 10.1016/j.jaip.2012.11.006. Epub 2013 Jan 12. PMID: 24565456
104. Wang H, Tighiouart M, Huang S, Berel D, Cook-Wiens G, Bresee C, Li Q, **Rogatko A**. The Integrated Web Portal for Escalation with Overdose Control (EWOC). The Open Medical Informatics Journal, 7: 18-23, May 2013. doi: 10.2174/1874431120130427001
105. Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA, Zayzafoon M, Hu P, Zhou H, Berel D, **Rogatko A**, Chung LW. Inhibition of β 2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One. 2013 Jul 10;8(7):e68366. doi: 10.1371/journal.pone.0068366.
106. Hu P, Chung L, Berel D, Frierson H, Yang H, Liu C, Wang R, Li Q, **Rogatko A**, Zhou H. Convergent RANK- and c-Met-mediated

- signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One. 2013 Sep 16;8(9):e73081. doi: 10.1371/journal.pone.0073081.
107. Lang JE, Holbrook JT, Wise RA, Dixon AE, Teague WG, Wei CY, Irvin CG, Shade D, Lima JJ; American Lung Association-Asthma Clinical Research Centers. Obesity in children with poorly controlled asthma: Sex differences. *Pediatr Pulmonol.* 2013 Sep;48(9):847-56. doi: 10.1002/ppul.22707. Epub 2012 Nov 9. PMID: 23143849
108. Asher A, Roberts PS, Bresee C, Zabel G, Riggs RV, **Rogatko A.** Transferring Inpatient Rehabilitation Facility Cancer Patients Back to Acute Care (TRIPBAC). *PM & R : the journal of injury, function, and rehabilitation.* 2014. Epub 2014/01/21. doi: 10.1016/j.pmrj.2014.01.009. PubMed PMID: 24440553.
109. Chu GC, Zhou HE, Wang R, **Rogatko A,** Feng X, Zayzafoon M, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. *Endocrine-related cancer.* 2014. Epub 2014/01/31. doi: 10.1530/erc-13-0548. PubMed PMID: 24478054.
110. Tighiouart M, Liu Y, **Rogatko A.** Escalation with Overdose Control using Time to Toxicity for Cancer Phase I Clinical Trials. 2014. PLoS ONE 9(3):e93070. PubMed PMID: 24663812
111. Tighiouart M, Piantadosi S, **Rogatko A.** Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Escalation with Overdose Control. *Statistics in Medicine.* 2014. doi: 10.1002/sim.6201. PMID: 24825779
112. Josson S, Gururajan M, Hu P, Shao C, Chu CY, Zhou HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, **Rogatko A,** Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. miR-409-3p/-5p Promotes Tumorigenesis, Epithelial to Mesenchymal Transition and Bone Metastasis of Human Prostate Cancer. 2014. *Clin Cancer Res.* Jun 24. PMID:24963047
113. Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhou HE, Liu C, Lichterman J, Duan P, Li Q, **Rogatko A,** Posadas EM, Haga CL, Chung LW. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. *Oncogene.* 2015 May 21;34(21):2690-9. doi: 10.1038/onc.2014.212. Epub 2014 Jul 28. PMID: 25065597
114. Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, **Rogatko A,** Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu R, Rossi M, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR. A translational, pharmacodynamic and pharmacokinetic phase IB clinical study of everolimus in resectable non-small cell lung cancer. *Clin Cancer Res.* 2015. Feb 11. PMID: 25673697

115. Zhang X, Li Q, **Rogatko A**, Tighiouart M, Hardison RM, Brooks MM, Kelsey SF, Kaul S, Bairey Merz CN. Analysis of the Bypass Angioplasty Revascularization Investigation Trial Using a Multistate Model of Clinical Outcomes. Am J Cardiol. 2015 Feb 2. PMID: 25724784
116. Lang JE, Holbrook JT, Mougey EB, Wei CY, Wise RA, Teague WG, Lima JJ; American Lung Association-Airways Clinical Research Centers. Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
117. Smith LJ, Kalhan R, Wise RA, Sugar EA, Lima JJ, Irvin CG, Dozor AJ, Holbrook JT; American Lung Association Asthma Clinical Research Centers. Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. JAMA. 2015 May 26;313(20):2033-43. doi: 10.1001/jama.2015.5024. PubMed PMID: 26010632. Ann Am Thorac Soc. 2015 Jun;12(6):878-85. doi: 10.1513/AnnalsATS.201408-391OC. PMID:25844821
118. Brodov Y, Gransar H, Dey D, Shalev A, Germano G, Friedman J, Hayes S, Thomson L, **Rogatko A**, Berman DS, Slomka PJ Combined Quantitative Assessment of Myocardial Perfusion and Coronary Artery Calcium Score by Hybrid 82Rb PET/CT Improves Detection of Coronary Artery Disease. J Nucl Med. 2015 Sep;56(9):1345-50. doi: 10.2967/jnumed.114.153429. PMID: 26159582.
119. **Rogatko A**, Cook-Wiens G, Tighiouart M, Piantadosi S. 2015. Escalation with Overdose Control is more Efficient and Safer than Accelerated Titration for Dose Finding. Entropy 17(8): 5288-5303; doi:10.3390/e17085288.
120. Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, Thomson LE, Berman DS, Shaw LJ, Petersen JW, Brown GH, Anderson RD, Shuster JJ, Cook-Wiens G, **Rogatko A**, Pepine CJ. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2015 Nov 27. PMID: 26614823
121. Tighiouart M, Li Q, **Rogatko A**. A Bayesian Adaptive Design for Estimating the Maximum Tolerated Dose Curve using Drug Combinations in Cancer Phase I. Statistics in Medicine. (in press)

B. Research Papers – Peer-Reviewed (Submitted)

C. Chapters:

1. Auerbach AD, **Rogatko A**, Schroeder TM. 1989. International Fanconi Anemia Registry (IFAR): First Report. In: Fanconi Anemia: Clinical, Cytogenetic and Experimental Aspects of

- Fanconi Anemia, Schroeder TM, Auerbach AD, Obe G, editors. Springer-Verlag, Heidelberg DE, pp 3-17.
2. **Rogatko A**, Zacks S. 1989. Statistical inference in the gene order problem: theoretical aspects. In: Genetic analysis workshop 6: multipoint mapping and linkage based upon affected pedigree members. Progress in clinical and biological research. Elston RC, Spence MA, Hodge SE, MacCluer JW, editors. A. R. Liss, New York NY, pp 63-68.
 3. Babb J, **Rogatko A**, Zacks S. 1998. Bayesian Sequential and Fixed Sample Testing of Multihypotheses. In: Asymptotic Methods in Probability and Statistics, Szyszkowicz B, editor. North-Holland, Amsterdam NL, pp 801-809.
 4. **Rogatko A**, Babb J, Rebbeck T. 1998. Genetic Counseling. In: Encyclopedia of Biostatistics, Armitage P, Colton T, editors. John Wiley & Sons, Chichester UK, vol. 2, pp 1672-1674.
 5. Khater C, Laub P, Gallo JM, **Rogatko A**, O'Dwyer PJ. 1997. Phase II Clinical Trials in Oncology. In: Anticancer Drug Development Guide, Teicher BA, editor. Humana Press, Totowa NJ, pp 249-270.
 6. Babb JS, **Rogatko A**. 2004. Bayesian Methods for Cancer Phase I Clinical Trials. In: Advances in Clinical Trial Biostatistics, N. Geller, editor. Marcel Dekker, New York NY, pp. 1-40.
 7. **Rogatko A**, Slifker MJ. 2004. Genetic Counseling. In: Encyclopedia of Human Genetics and Genetic Epidemiology, Elston R, Olson J, Palmer L, editors. John Wiley & Sons, Hoboken NJ.
 8. Zacks S, **Rogatko A**. 2004. Bayesian Sequential Procedures for Ordering Genes. In: Applied Sequential Methodologies, Mukhopadhyay N, Datta S, Chattopadhyay S, editors. Marcel Dekker, New York NY, pp 411-432.
 9. Tighiouart M, **Rogatko A**. 2006. Dose Finding in Oncology – Parametric Methods. In: Dose Finding in Drug Development, Ting N, editor. Springer, New York NY, pp 59-72.
 10. Tighiouart M, **Rogatko A**. 2006. Dose-escalation with overdose control. In: Statistical Methods for Dose-Finding Experiments, Chevret S, editor. John Wiley & Sons, Hoboken NJ, pp 173-188.
 11. **Rogatko A**, Tighiouart M. 2007. Novel and Efficient Translational Clinical Trial Designs in Advanced Prostate Cancer. In: Contemporary Cancer Research: Prostate Cancer: Biology, Genetics, and the New Therapeutics, Chung LWK, Isaacs WB, Simons JW, editors. Humana Press, Totowa NJ, pp 487-495.
 12. **Rogatko A**, Piantadosi S. 2015. Problems with Constructing Tests to Accept the Null Hypothesis. In: Interdisciplinary Bayesian Statistics: EBEB 2014, Polpo de Campos A, Louzada F, Ramos Rifo L, Stern JM, Lauretto M, editors. Springer International Publishing, New York NY, pp 49-54.

13. **Rogatko A**, Tighiouart M. 2015. Dose Finding with Escalation with Overdose Control in Cancer Clinical Trials. In: Clinical Trial Biostatistics and Biopharmaceutical Applications, Young WR, Chen DG, editors. CRC Press, Boca Raton FL, pp 274-305.
- D. Chapters (In Press)
- E. Letters to the Editor:
- Rogatko A**, Litwin S. 1996. Phase II studies: which is worse, false positive or false negative? J. Natl. Cancer Inst., Letter 88:461.
- F. Reviews:
- Rogatko A**. 2007. Book Review, Statistical Concepts and Applications in Clinical Medicine, by Aitchison, J., Kay, J. W., Lauder, I. J., Statistics in Medicine, 26(4), 943 – 944.
- G. Symposia:
1. Pereira CAB, Gomes-Neto JBF, Bezerra RCF, **Rogatko A**. 1985. Inversão de condicionamento. Proceedings of the 6th National Symposium of Probability and Statistics. Rio de Janeiro.
 2. Monteleone-Neto R, **Rogatko A**, Chien YT. 1985. Birth defects and environmental pollution: The Cubatão example. In: Prevention of Physical and Mental Congenital Defects, pp. 65-68. Proceedings of the International Conference of the Institut de la vie, Strasbourg, France, October 1982, AR Liss, New York.
 3. **Rogatko A**, Babb J, Zacks S. 1995. Statistical issues in gene mapping and risk assessment. In: American Statistical Association, 1995 Proceedings of the Epidemiology Section, pp.28-37.
 4. Wang H, **Rogatko A**, Smarandache F, Sunderraman R, "A Neutrosophic Description Logic", Proc. of IEEE-GrC 2006, May, 2006
 5. Wang H, Lee J, Buck K, Xu Z, Tighiouart M, Hubbard C, **Rogatko A**. "Lung Cancer Clinical Application System", Proc. of BIRD 2007, March.
 6. Tighiouart, M, **Rogatko A**, Xu, Z. 2007. Incorporating patient's characteristics in cancer phase I clinical trials using escalation with overdose control. JSM Conference Proceedings, Section on Bayesian Approaches to Clinical Trials.
 7. Xu, Z, Wang, H, Tighiouart, M, **Rogatko A**. 2007. EWOC Online: An Interactive Web Tool for Dose Escalation in Cancer Phase I Clinical Trials. JSM Conference Proceedings, Section on Use of Bayesian Statistics in Phase-I Clinical Studies.
 8. **Rogatko A**, Cook-Wiens G, Tighiouart M, Piantadosi S. 2013. FDA and Innovative Designs: Case Study of a Missed

Opportunity. In JSM Proceedings, pp 3275-3288. Alexandria, VA: American Statistical Association.

9. **Rogatko A**, Piantadosi S. Problems with Constructing Tests to Accept the Null Hypothesis. Proceedings of the 12th Brazilian Meeting on Bayesian Statistics (EBEB 2014). Springer Proceedings in Mathematics & Statistics. Springer International Publishing, New York NY, pp 49-54.

H. Computer Software:

1. **Rogatko A**. 1994. METABAY user's manual. Version 0.0. Technical Report, Dep. of Biostatistics, Fox Chase Cancer Center, Philadelphia, 22 pp.
2. Jordan H, **Rogatko A**. 1995. SSMAP: a computer implementation of the step-wise search for the maximal posterior algorithm. Version 1.0. Technical Report, Dep. of Biostatistics, Fox Chase Cancer Center, Philadelphia, 12 pp.
3. Jordan H, **Rogatko A**. 1995. Comprisk: compound risk calculation with linked markers. Version 0.0. Technical Report, Dep. of Biostatistics, Fox Chase Cancer Center, Philadelphia, 10 pp.
4. **Rogatko A**, Babb J. 1998 . Escalation with overdose control. User's guide. Version 1.beta. The URL address is http://www.fccc.edu/users/rogatko/user_guide.html.
5. **Rogatko A**, Slifker M. 1999. HWDIAG - Diagnostics for Hardy-Weinberg Equilibrium: User's guide. Version 1.beta. The URL address is <http://www.fccc.edu/users/rogatko/hwdiag/hwdiag.html> and <http://www.sph.emory.edu/BRI-WCI/hwdiag.html>.
6. **Rogatko A**, Xu R. 2005. Escalation with overdose control. User's guide. Version 2. The URL address is <http://www.sph.emory.edu/BRI-WCI/ewoc.html>.
7. **Rogatko A**, Tighiouart M, Cook-Wiens G. 2012. Escalation with overdose control. User's guide. Version 3.1. The URL address is <http://biostatistics.csmc.edu/ewoc/>
8. **Rogatko A**, Tighiouart M, Bresee C. 2012. Escalation with overdose control. User Guide Web-Based Portal. The URL address is <http://biostatistics.csmc.edu/ewoc/>
9. **Rogatko A**, Tighiouart M. 2013. Designing a Dose Finding Trial using EWOC. The URL address is <http://biostatistics.csmc.edu/ewoc/>